Oncolytics Biotech (NASDAQ:ONCY) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY - Free Report) in a research note issued to investors on Thursday, Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock.

Get Oncolytics Biotech alerts:

Oncolytics Biotech Trading Up 2.2 %

Shares of NASDAQ:ONCY traded up $0.02 during trading on Thursday, reaching $0.95. 229,426 shares of the stock were exchanged, compared to its average volume of 265,951. The firm has a market cap of $72.50 million, a PE ratio of -3.23 and a beta of 1.80. Oncolytics Biotech has a 12 month low of $0.85 and a 12 month high of $2.30. The stock has a 50-day moving average price of $0.99 and a 200-day moving average price of $1.04.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. During the same period last year, the business earned ($0.09) earnings per share. On average, sell-side analysts expect that Oncolytics Biotech will post -0.29 earnings per share for the current fiscal year.

Institutional Trading of Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC bought a new position in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 51,889 shares of the company's stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Oncolytics Biotech as of its most recent filing with the SEC. 6.82% of the stock is owned by institutional investors and hedge funds.

Ad Porter & Company

War on Elon Escalates…

Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

Click here to learn how you can benefit from its widespread distribution.

Oncolytics Biotech Company Profile

(Get Free Report)

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.

Should you invest $1,000 in Oncolytics Biotech right now?

Before you consider Oncolytics Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.

While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report